3,3',5-triiodothyroacetic acid has been researched along with Thyroid Neoplasms in 7 studies
tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten athyreotic patients, treated for thyroid carcinoma, were randomly assigned to receive L-T4 sodium 0." | 2.67 | Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. ( Ladenson, PW; Sherman, SI, 1992) |
| "Thyroid hormone resistance syndrome is characterized by a reduced target tissue response to the action of thyroid hormone, which leads to high levels of free thyroxine and free triiodothyronine with non-suppressed levels of thyrotropin (TSH)." | 1.39 | Differentiated thyroid carcinoma in a girl with resistance to thyroid hormone management with triiodothyroacetic acid. ( Antonia Pérez-Lázaro, M; Isabel del Olmo-García, M; León-de Zayas, B; Merino-Torres, JF; Moreno-Macián, F; Navas-de Solis, S; Ramos-Prol, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos-Prol, A | 1 |
| Antonia Pérez-Lázaro, M | 1 |
| Isabel del Olmo-García, M | 1 |
| León-de Zayas, B | 1 |
| Moreno-Macián, F | 1 |
| Navas-de Solis, S | 1 |
| Merino-Torres, JF | 1 |
| Jaffiol, C | 2 |
| Daures, JP | 1 |
| Nsakala, N | 1 |
| Guerenova, J | 1 |
| Baldet, L | 1 |
| Pujol, P | 2 |
| Vannereau, D | 1 |
| Bringer, J | 2 |
| Osman, A | 1 |
| Sherman, SI | 1 |
| Ladenson, PW | 1 |
| Mechelany, C | 1 |
| Schlumberger, M | 1 |
| Challeton, C | 1 |
| Comoy, E | 1 |
| Parmentier, C | 1 |
| Langer, HJ | 1 |
| Leicht, E | 1 |
| Koch, B | 1 |
| Weinheimer, B | 1 |
| Berberich, R | 1 |
| Strohfeldt, P | 1 |
| Weinges, KF | 1 |
| Mueller-Gaertner, HW | 1 |
| Schneider, C | 1 |
1 trial available for 3,3',5-triiodothyroacetic acid and Thyroid Neoplasms
| Article | Year |
|---|---|
Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects.
Topics: Adult; Aged; Bone and Bones; Female; Humans; Liver; Male; Metabolism; Middle Aged; Pituitary Gland; | 1992 |
6 other studies available for 3,3',5-triiodothyroacetic acid and Thyroid Neoplasms
| Article | Year |
|---|---|
Differentiated thyroid carcinoma in a girl with resistance to thyroid hormone management with triiodothyroacetic acid.
Topics: Carcinoma; Carcinoma, Papillary; Cell Differentiation; Child; Female; Humans; Thyroid Cancer, Papill | 2013 |
[Long term follow up of medical treatment of differentiated thyroid cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up | 1995 |
Prevention of thyroid neoplasm recurrence with Triac and levothyroxine.
Topics: Carcinoma; Drug Therapy, Combination; Humans; Neoplasm Recurrence, Local; Thyroid Neoplasms; Thyroxi | 1997 |
TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine.
Topics: Depression, Chemical; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism | 1991 |
[Familial nonneoplastic inappropriate thyrotropin secretion].
Topics: Carcinoma; Diagnosis, Differential; Drug Therapy, Combination; Female; Goiter; Humans; Middle Aged; | 1990 |
3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma.
Topics: Adult; Aged; Depression, Chemical; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pit | 1988 |